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A recently recognized syndrome of acquired immunodeficiency (Acquired Immunodefi-
*ciency Syndrome-AIDS) has arisen since June 1981. It has received international attention.
The clinical spectrum consists of repeated opportunistic infections, rare malignancies, and
autoimmune phenomena, occurring in previously healthy adults with no history of an im-
munologic disorder. The population subset at risk for this syndrome appears to be predomi-
nantly homosexual American males and intravenous drug abusers with rare cases being
reported in heterosexuals, hemophiliacs, and foreign patients, especially Haitians. The im-
munologic aberrancy in all patients described appears limited to T-lymphocyte hyporespon-
siveness and imbalance ofT-helper and suppressor cells. This disordered immunoregulation is
a consistent finding in all reported cases and appears to predispose to the opportunistic infec-
tions and malignancies which have been associated with a 40 percent mortality. The underlying
factor responsible for the immunoregulatory defect is unknown but possible etiologies include
a transmissable infectious agent, drug use, chronic antigen stimulation, and spermatozoa ex-
posure. Treatment of the associated infections and malignancies has been a frustrating
endeavor as many patients respond incompletely or relapse soon after successful treatment
course. Preventive measures, including patient education, physician awareness, and immuno-
modulating agents, are discussed.
INTRODUCTION
The clinical syndrome of acquired immunodeficiency is one that has received na-
tional and international attention since its original description in June 1981. This
widespread attention is ofno surprise as the syndrome is not onlyofmedical interest
with respect to immunology, infectious disease, and oncology, but has devastating
epidemiologic and social implications. Despite preliminary research and mounting
clues, the etiology of the syndrome is still not defined. Hence, the purpose of this
review is to describe what is the current status of the epidemiologic, oncologic, and
immunologic concepts of this syndrome, evaluate some possible etiologic agents,
and touch on the implications of therapy and prevention.
EPIDEMIOLOGY
The history of the syndrome dates to June 1981 when the CDC reported the un-
precedented occurrence ofpneumocystis carinii pneumonia (PCP) in five previously
healthy homosexual men-all five of whom had documented cytomegalovirus
(CMV) infections and reported use ofinhalant drugs [1]. Soon thereafter, numerous
reports began to appear of the alarming occurrence of PCP as well as other oppor-
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tunistic infections, in addition to Kaposi's sarcoma (a previously rarely reported
neoplasm of elderly men, equatorial Africans, and immunosuppressed patients) in
previously healthy homosexual males [1-6].
Over the ensuing year, increasing numbers of recognized cases have been reported
to CDC with two new patterns emerging:
First, the disease spectrum has expanded to include (aside from PCP and Kaposi's
sarcoma) virtually every known opportunistic infection (including disseminated can-
dida, cryptococcus, mycobacteria and herpes virus [7]), other rare malignancies (in-
cluding squamous cell CA of tongue and diffuse undifferentiated lymphoma [8]),
autoimmune phenomena (including ITP and autoimmune hemolytic anemia [9]), as
well as a poorly defined "prodromal syndrome" consisting ofchronic fever, fatigue,
and generalized lymphadenopathy (which often preceded development of malig-
nancies and/or opportunistic infections [10]).
Second, the population at risk is not limited to homosexual men, but has ex-
panded to include heterosexual men and women (most of whom were intravenous
drug abusers) [11], Haitian immigrants recently entering the U.S.A. [12], and most
recently three hemophiliacs [13].
Most alarming, perhaps, are the increasing numbers of cases being reported (ap-
proximately three cases per day to CDC) and a devastating 40 percent mortality (a
rate that exceeds 60 percent for those patients diagnosed over a year ago- see Fig. 1)
[7]. Indeed, this newly recognized syndrome has accounted for more deaths than the
combined total attributed to toxic shock syndrome and the Philadelphia outbreak of
Legionnaire's disease [2].
The current tabulated figures as of November 1982 are as follows [14]:
Total cases: 691
Location: 639 USA, 52 foreign (Haiti, Canada, Europe, Argentina, and
Japan)
Patient characteristics: 75 percent homosexual or bisexual males
12 percent intravenous (IV) drug abusers
6 percent Haitian immigrants
6 percent other (i.e., hemophiliacs, heterosex-
uals)
Total deaths: 278
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IMMUNOLOGIC PATTERNS
Upon examination of the clinical syndromes with which these patients were pre-
senting (i.e., opportunistic infections, rare malignancies), it became clear that the
common link among all of them was a profound disorder of immunoregulation-
and this disorder appeared confined to the cellular arm of the immune response.
In order to interpret more clearly the implications of the observed immune status
that has been described in these patients, let us briefly review what is the current con-
ceptual model of the character and function of human T cells (see Fig. 2) [15].
Precursor prothymocytes migrate from the bone marroW to the thymus where
they are processed in three stages (as manifest by changes in cell surface antigens),
become functionally competent, and are exported to the peripheral lymphoid com-
partment. Stage I (10 percent of the thymocyte population) represents the earliest
lymphoid cells bearing immature antigens shared by bone marrow cells of several
lineages. With further maturation, cells enter Stage 11 (70 percent of thymocytes)
where they develop thymocyte distinct antigens (i.e., T4, Ts, and T8 as defined by
monoclonal antibody techniques). Upon entrance into Stage III (20 percent of
population), immunologic competence is acquired, and cells segregate antigenically
into T4+ and T5+/T8+ subsets which are mutually exclusive [15-18].
Functional studies of isolated subpopulations of peripheral T cells have demon-
strated that this expression of a particular cell surface antigen is linked to specific
cell function. That is, the T4+ population has been shown to exclusively possess an
assigned inducer role in T-T, T-B, and T-macrophage interactions, whereas the T5+/
T8+ subset demonstrates only cytotoxic/suppressor function (refer to Table 1) [18].
Furthermore, surface antigen differentiation appears even more complex as further
studies have demonstrated functional heterogeneity within the T4+ subset (i.e., a
population which induces help, and a population which induces suppression- see
Fig. 3) [18]. Thus, one should be cautioned that measurement of T4+/T8+ subset
ratios in vitro (as has been done in patients with AIDS) is a convenient assay, yet
crude representation of in vivo immune status.
Given this background, what are the recognized immune defects in patients with
AIDS? With repeated investigations, clinicians and scientists alike have observed a
consistent pattern. In vivo, patients were noted to be profoundly lymphopenic, as
well as anergic to a multitude of skin test antigens (e.g., candida, PPD). More inter-
estingly, in vitro, patients' lymphocytes were found to demonstrate T-cell depletion,
diminished proliferative response to mitogens (i.e., ConA, PHA), and a much pub-
licized imbalance of T4+ (helper)/T8+ (suppressor) ratio in favor of suppression
(humoral responses appear normal or increased) (refer to Table 2) [19-22].
Stage %7o of Thymocyte Population Antigenic Characteristics
I 10 Tio, T,
AI 70 Tio, , T T4, Ts, T8
20 Tio, T,, T34 T ,, T,, T3, T,, T8
(helper) (suppressor)
FIG. 2. Stages of human T-cell differentiation (adapted from [15]).
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TABLE 1
Functional Characteristics of T-Cell Subsets*
T Inducer T Cytotoxic/Suppressor
Function (T,, T3, T4) (T,, T3, Ts, Ts)
Proliferative Response
MLC + +
Con A + +
Regulatory Events
Helper (inducer)
T-T + -
T-B + -
T-macrophage +
Suppression
T-T - +
T-B - +
*Adapted from [181
This pattern of immune deficiency has been demonstrated repeatedly in the cases
reported over the past year to CDC. However, ongoing investigation has revealed
some new and interesting observations regarding the immune dysfunction in these
patients. First, the T-helper/T-suppressor imbalance seen in patients with AIDS ap-
pears also to be present in healthy homosexual controls as well (albeit to a lesser
degree). In a recent study of 81 healthy homosexual males in New York City, 80 per-
cent showed altered distribution ofT-cell subsets [23]. The implication ofthis is that
we may just have encountered "the tip of the iceberg" and the number of persons at
risk for serious illness may be much larger than is indicated by the reported cases.
Second, there appears to be a gradation of ratio imbalance among the various clini-
cal subsets of AIDS with the patients developing opportunistic infections demon-
strating the most severe imbalance (refer to Table 3). Furthermore, on follow up of
these patients (three to six months), ratios have remained unchanged despite effec-
tive treatment of opportunistic infections or KS [24]. Third, some immunologic
features ofpatients with KS or unexplained lymphadenopathy resemble those found
in patients with autoimmune disorders-including abnormal T-cell subsets, poly-
clonal hyperglobulinemia, circulating immune complexes, and an unusual acid labile
from of human leukocyte interferon (HuIFN-a) in their serum (seen in manypatients
with SLE) [25]. Finally, investigators from New York University have demonstrated
Thymus Bursal Equivalent
II
su ids)nd )h) cell
plasma
Antibody
effector cells
* T ind(s) T inducer of suppression
T ind (h) T inducer of help
FIG. 3. The human T-cell scheme (adapted from [181).
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TABLE 2
In Vitro Characteristics of Four Patients with AIDS*
Mean Mean Mean % Mean T
WBC Lymphocyte E Rosette Helper/Suppressor
Count Count Formation Ratio
Patients 3186 418 52 0.06
Normal range 4800-10,800 1440-3040 59-74 0.86-2.34
*Adapted from [211
an increased frequency of HLA DR5 haplotypes in homosexual as well as non-
homosexual males with KS. This observation suggests that specific immune response
genes in linkage dysequilibrium with DR5 may genetically predispose a patient to
this opportunistic malignancy [26].
In summary, depending on thegenetic substrate ofthe host and the severity ofthe
underlying immune defect, a given patient may develop KS, opportunistic infection,
autoimmune disease, or a combination of all.
ETIOLOGIC AGENTS
With respect to potential etiologies three key questions arise. Does this represent a
new virus or other infectious agent which is first becoming manifest in the homo-
sexual community due to the high exposure potential within this group? Do recre-
ational drugs have a direct causative role or merely represent an epiphenomenon?
Does the immunosuppression relate to chronic, repeated antigen exposure?
The possibility that an infectious agent represents the ultimate underlying cause
stems from three epidemiologic observations. One is the geographic clustering of
cases in major cities (New York, Los Angeles, and San Francisco), suggesting com-
mon sources ofpossible primary infectious factors [27,28]. Second, the host pattern
emerging (i.e., homosexuals, hemophiliacs, IV drug abusers) represents the distribu-
tion of disease by common transmissable agents (e.g., hepatitis B virus). Third,
homosexual men with multiple sexual partners are at increased risk ofacquiring sex-
ually transmitted disease-including traditional VD (GC, syphilis), viral hepatitis,
CMV, and multiple enteric pathogens (including giardia, shigella, amebiasis) col-
lectively referred to as the "gay bowel syndrome" [29-31].
Considering the innumerable transmissable infectious agents, CMV has received
most attention, and there are several reasons for this. One is that evidence of
previous or current CMV infection is a unifying presence in all the CDC case reports
TABLE 3
Ratio Imbalance by Various Clinical Subsets*
OK T4/T8 Ratio
Control 1.75
Heterosexual with KS 1.79
Healthy homosexual male 1.1
Homosexual male with prodrome 0.7
Homosexual male with KS 0.48
Homosexual male with opportunistic 0.17
infections
KS-Kaposi's sarcoma
*Adapted from [24]
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(though the CMV isolated does not appear to represent a new, more virulent strain).
Indeed, previous studies have shown that homosexual males are at greater risk for
developing CMV infections than heterosexual males (i.e., approximately 95 percent
have positive antibody titers to CMV and 10 percent have active viruria), felt to be
primarily due to exposure to infected semen in which CMV persists for up to 18
months [32-33]. Second, acute CMV infection has been shown to be associated with
a similar pattern of T-cell imbalance as seen in patients with AIDS-namely, an in-
creased number of cytotoxic/suppressor (T8+) cells and a decreased number of
helper cells (T4+) associated with lymphocyte hyporesponsiveness to mitogens
(ConA). Furthermore, this T-cell imbalance has been documented to last for up to
ten months [34-37]. In addition, CMV has been shown in clinical studies of renal
transplant recipients to be associated with a high rate of superinfection, especially
PCP. Although this clearly could be related to the underlying immunosuppressed
state of these patients, CMV has been shown to directly depress alveolar macro-
phage function in the murine model [38], and thus may predispose at a local level,
along with systemic T-cell imbalance, to superinfecting pneumonia. Finally, increas-
ing evidence has supported the association of CMV and Kaposi's sarcoma, an asso-
ciation proposed by Giraldo in 1972 when a CMV strain was isolated from a KS
tissue biopsy in culture. Since then, he and several other investigators have demon-
strated an increased incidence ofCMV antibodies in European and American KS pa-
tients as well as CMV DNA and RNA sequences detected recently from tumor biop-
sies of ten KS patients [39-43].
The hypothesis that CMV is the ultimate underlying etiology for AIDS suffers
from two major flaws. One is that patients who are immunosuppressed for other
reasons (e.g., steroids) also have a high incidence of CMV infection; thus the
immunosuppression seen in these patients may have another etiology which second-
arily allows for CMV reactivation. A second flaw is that CMV is not a new infec-
tious agent and homosexuality as a lifestyle has been around for centuries, so this
hypothesis does not explain why AIDS is apparently new.
Hence, the search has continued for a new epidemiologic factor and has led in-
vestigators to suspect the recent popularity ofdrug use as a possible etiologic factor.
Support for the "drug hypothesis" dates back to the original five cases reported in
June 1981, and stems from the facts that recreational drugs are widely used in large
cities and that the majority of non-homosexual AIDS patients reported were drug
users. Of all the potential candidate drugs, amyl nitrite has been a leading possibility
for the homosexual community with AIDS, as it is commonly used to intensify
orgasm [44]. It is currently unclear from available data whether nitrite use has a
direct effect on T-cell function or whether it represents a certain lifestyle that may
predispose to transmission of an infectious agent.
For example, in a study of 150 homosexual men, it was found that users of amyl
nitrite had a higher incidence of multiple sexual partners, group sex, and venereal
disease [44]. Conversely, ongoing studies of KS patients at New York University
have revealed that, using multivariate analysis, both multiple sexual partners (> 10
per year) and amyl nitrite use were independent risk factors for KS development
[43,45]. Thus, until more data are collected, the role of amyl nitrite as a direct
causative factor remains unclear.
Assuming that CMV and amyl nitrite use may be potential candidate etiologies for
the homosexual community, how do we explain the emergence of this syndrome in
the IV opiate user? Actually, immunologic abnormalities in IV opiate addicts have
been clinically observed for over a decade (e.g., hypergammaglobulinemia, false a)
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VDRL), but it was not until recently that the immune dysfunction has been better
characterized. In a study of 38 heroin addicts [46], in vitro lymphocyte respon-
siveness to mitogen stimulation was impaired compared to controls. The authors
hypothesized that chronic antigen stimulation can lead to a "hyperimmunized state"
wherein hypergammaglobulinemia and aberrant antibody formation could occur
(e.g., e VDRL), with serum factors emerging that could temporarily affect lym-
phocyte function. This concept is further supported by more recent studies demon-
strating evidence for opiate receptors on lymphocytes in vitro, as well as depression
of T-cell number and function in vivo opiate addicts (refer to Table 4) [47]. In this
same study, these effects were reversed by naloxone (an opiate antagonist), thus sup-
porting the hypothesis of a direct opiate effect on lymphocytes. In addition to the
potential immunologic effects of chronic antigen stimulation (i.e., via injection of
particulate matter) and a potential transmissable agent, IV opiate abusers may
develop immune dysfunction as a result of a direct opiate-lymphocyte interaction.
Perhaps the most exciting potential candidate etiology (with respect to homo-
sexual patients at least) is that of spermatozoa exposure. Indeed, there has been in-
terest in germ cell-induced immunosuppression prior to the recognition of AIDS.
Much ofthe work has been done at NIH where investigators have demonstrated that
theinjection ofsperm (syngeneic orallogeneic) intothebloodstream ofmice induced
an increased suppressor cell activation, and profound suppression of cell-mediated
functions. It was postulated that germ cells expressing embryonic antigens enter the
circulation and generate an immunologic suppressor reaction to protect the host
from an autoimmune response [48-50]. Interest in this hypothesis as a mechanism
for immunosuppression in AIDS has been sparked recently by New York University
investigators who havedetected antisperm antibody that cross-reacted with T cells in
the circulation of twelve KS patients, all of whom were azospermic on testicular
biopsy [24]. Therefore, in homosexual males, sperm may reach the bloodstream via
intestinal mucosal lesions (perhaps enhanced by nitrite-induced vasodilation) and
lead to immunosuppression independently (viaantisperm antibodycoating ofT cells
enhancing their destruction in RE system), or as a carrier of viruses.
In conclusion, it is likely that the immunosuppression seen in patients with AIDS
is multifactorial with different etiologic possibilities acting alone or synergistically in
different populations, with the clinically observable syndrome dependent on host
susceptibility.
TREATMENT
Treatment of this complex syndrome which presents with a variety of clinical
manifestations, has been a frustrating endeavor for all clinicians. Opportunistic in-
fections must be treated individually but this often is a fruitless battle, as patients
TABLE 4
Mean White Blood Cell and T Lymphocyte Numbers
in IV Addicts and Controls*
Controls Addicts
Patients 28 44
Mean WBC 7210 7287
Gb B cells 17.8 16.3
% T cells 69.1 27.5
*Adapted from [471
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TABLE 5
Kaposi's Sarcoma in AIDS-Therapeutic Experience*
No. of Complete Partial No
Patients Remission Remission Remission
Chemotherapy (NYU Data)
VP16 19 4 (2 relapsed) 13 2
ABVa 20 4 (3 relapsed) 14 2
Immunotherapy (Sloan-Kettering)
Interferon 12 1 7 4
0ABV = adriamycin, bleomycin, and Velban
*Adapted from [24]
frequently relapse with multiple opportunistic infections. Initial chemotherapy trials
for KS in AIDS patients have revealed similar though somewhat more encouraging
results with approximately 20 percent of patients achieving a complete remission
(Table 5) [24]. Of the potential immunotherapeutic agents, interferon appears most
promising, as it possesses antiviral, antiproliferative, and immunomodulating prop-
erties. Other immunologic modalities have met with minimal success and have in-
cluded thymosin (no response in three patients), bone marrow transplantation (un-
successful in one patient), as well as transfer factor and plasmapheresis [24].
Potential oral agents ofuse, both as adjunctive and possibly preventive as well, in-
clude isoprinosine, an agent available only in Europe which has been shown to im-
prove lymphocyte activity as well as to increase the relative number ofT-helper cells.
In the U.S.A., cimetidine has been proposed as a potentially effective agent based
on the fact that histamine, in a reversible dose-response fashion, inhibits cell-
mediated immunity. Indeed, there has been one published report [51] of its use in
four patients with chronic mucocutaneous candidiasis with encouraging results as an
immunomodulator, but its use in AIDS patients is as yet unproven.
PREVENTION
Preventing expansion of this devastating epidemic can be approached from four
potential fronts. First is physician awareness of the problem and the routine man-
datory taking of sexual histories (especially in patients presenting with pneumonia,
skin nodules, prolonged fever, or generalized unexplained lymphadenopathy). Sec-
ond, to prevent in-hospital spread ofapotentially infective agent, it appears prudent
for physicians to observe the same precautions for AIDS patients as for patients
with hepatitis B virus infection [52]. Third, prophylactic antibiotic therapy (i.e.,
trimethoprim-sulfamethoxazole), as used in other high-risk populations for PCP, is
likely to be useful in these patients but fraught with danger as most patients at risk
are already profoundly leukopenic. Thus further bone marrow suppression (seen
commonly inthese patients treated with this agent) may preclude its benefit as a pro-
phylactic agent.
Finally, perhaps the most important role for physicians lies in patient education.
At present, with the available dataregarding potential risk factors, one should prob-
ably recommend decreased drug use and decreased numbers of sexual partners to
homosexual patients. However, one should stress that this is purely a medical
recommendation as its emotional, social, and ethical implications may be as devas-
tating as the illness one is trying to prevent.
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